Eyenovia (EYEN) Stock Price, News & Analysis

Company Overview

Eyenovia, Inc. is a clinical‐stage ophthalmic biopharmaceutical company dedicated to developing microdose-based treatments for common eye disorders. Leveraging its proprietary Optejet® platform, the company delivers precise, low-volume doses of established and novel therapeutic agents directly to the ocular surface. This targeted approach is designed to enhance drug efficacy while minimizing side effects, positioning Eyenovia at the forefront of innovation in eye‐care delivery systems.

The company’s lead programs include MicroLine®, a topical treatment for presbyopia that uses a combination of low-concentration muscarinic agonists to restore near vision, and MiDrops™, an investigational formulation aimed at slowing the progression of myopia in children. Both products employ the Optejet platform’s high-precision microdosing technology to administer doses of less than 10 microliters, enabling consistent delivery and improved patient compliance. Eyenovia continues to advance these candidates through late-stage clinical trials and regulatory interactions across key markets.

Founded in 2010 and headquartered in Marlborough, Massachusetts, Eyenovia operates research and development facilities in the United States and maintains strategic partnerships to support future commercialization efforts worldwide. Under the leadership of Chief Executive Officer Anthony E. Adamis, M.D., the company has expanded its management team and board of directors to include seasoned professionals with deep expertise in ophthalmology, clinical development, and regulatory affairs. This experienced leadership group is driving Eyenovia’s mission to transform the standard of care for patients affected by visual disorders.

Key Stats

• Today's Range: $10.70 to $17.18
• 50-Day Range: $1.04 to $15.96
• 52-Week Range: $0.85 to $124.80
• Volume: 4.63 million shs
• Average Volume: 1.26 million shs
• Market Capitalization: $45.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

Eyenovia Stock Analysis - MarketRank™

Eyenovia scored higher than 20% of companies evaluated by MarketBeat, and ranked 845th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Eyenovia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eyenovia has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eyenovia are expected to grow in the coming year, from ($41.60) to ($16.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eyenovia is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eyenovia is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.05% of the float of Eyenovia has been sold short.

Short Interest Ratio / Days to Cover

Eyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eyenovia does not currently pay a dividend.

Dividend Growth

Eyenovia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.05% of the float of Eyenovia has been sold short.

Short Interest Ratio / Days to Cover

Eyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.40

News Sentiment

Eyenovia has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Eyenovia this week, compared to 2 articles on an average week.

Search Interest

25 people have searched for EYEN on MarketBeat in the last 30 days. This is an increase of 127% compared to the previous 30 days.

MarketBeat Follows

1 people have added Eyenovia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eyenovia insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of Eyenovia is held by insiders.

Percentage Held by Institutions

Only 25.84% of the stock of Eyenovia is held by institutions.

EYEN Stock Analysis - Frequently Asked Questions

How have EYEN shares performed this year?

Eyenovia's stock was trading at $11.68 at the start of the year. Since then, EYEN stock has increased by 36.6% and is now trading at $15.96.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) released its quarterly earnings results on Monday, May, 19th. The company reported ($1.59) earnings per share for the quarter, beating analysts' consensus estimates of ($7.20) by $5.61. The firm earned $1.60 million during the quarter, compared to analysts' expectations of $1.60 million.

When did Eyenovia's stock split?

Eyenovia's stock reverse split on the morning of Monday, February 3rd 2025.The 1-80 reverse split was announced on Tuesday, January 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did Eyenovia IPO?

Eyenovia (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eyenovia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eyenovia investors own include Plug Power (PLUG), Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Pfizer (PFE), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/19/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EYEN
• CIK: 1682639
• Web: www.eyenoviabio.com
• Phone: (917) 289-1117
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eyenovia: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: -87.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($58.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.82 million
• Net Margins: -62,238.41%
• Pretax Margin: -62,238.41%
• Return on Equity: N/A
• Return on Assets: -316.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 766.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($695.52) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 2,880,000
• Free Float: 2,678,000
• Market Cap: $45.96 million
• Optionable: Optionable
• Beta: 2.47